These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model. Riedel G; Klein J; Niewiadomska G; Kondak C; Schwab K; Lauer D; Magbagbeolu M; Steczkowska M; Zadrozny M; Wydrych M; Cranston A; Melis V; Santos RX; Theuring F; Harrington CR; Wischik CM Curr Alzheimer Res; 2020; 17(3):285-296. PubMed ID: 32091331 [TBL] [Abstract][Full Text] [Related]
4. Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate. Wischik CM; Bentham P; Gauthier S; Miller S; Kook K; Schelter BO J Prev Alzheimers Dis; 2022; 9(4):780-790. PubMed ID: 36281683 [TBL] [Abstract][Full Text] [Related]
5. Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium. Seripa D; Solfrizzi V; Imbimbo BP; Daniele A; Santamato A; Lozupone M; Zuliani G; Greco A; Logroscino G; Panza F Expert Rev Neurother; 2016; 16(3):259-77. PubMed ID: 26822031 [TBL] [Abstract][Full Text] [Related]
12. Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease. Baddeley TC; McCaffrey J; Storey JM; Cheung JK; Melis V; Horsley D; Harrington CR; Wischik CM J Pharmacol Exp Ther; 2015 Jan; 352(1):110-8. PubMed ID: 25320049 [TBL] [Abstract][Full Text] [Related]
13. Proteomic Analysis of Hydromethylthionine in the Line 66 Model of Frontotemporal Dementia Demonstrates Actions on Tau-Dependent and Tau-Independent Networks. Schwab K; Melis V; Harrington CR; Wischik CM; Magbagbeolu M; Theuring F; Riedel G Cells; 2021 Aug; 10(8):. PubMed ID: 34440931 [TBL] [Abstract][Full Text] [Related]
14. Editorial: Targets for Disease-Modifying Therapies in Alzheimer's Disease, Including Amyloid β and Tau Protein. Parums DV Med Sci Monit; 2021 Jul; 27():e934077. PubMed ID: 34305135 [TBL] [Abstract][Full Text] [Related]
15. Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease. Harrington CR; Storey JM; Clunas S; Harrington KA; Horsley D; Ishaq A; Kemp SJ; Larch CP; Marshall C; Nicoll SL; Rickard JE; Simpson M; Sinclair JP; Storey LJ; Wischik CM J Biol Chem; 2015 Apr; 290(17):10862-75. PubMed ID: 25759392 [TBL] [Abstract][Full Text] [Related]
16. Tau Biology and Tau-Directed Therapies for Alzheimer's Disease. Bakota L; Brandt R Drugs; 2016 Mar; 76(3):301-13. PubMed ID: 26729186 [TBL] [Abstract][Full Text] [Related]
17. Molecular Insight into the Therapeutic Promise of Flavonoids against Alzheimer's Disease. Uddin MS; Kabir MT; Niaz K; Jeandet P; Clément C; Mathew B; Rauf A; Rengasamy KRR; Sobarzo-Sánchez E; Ashraf GM; Aleya L Molecules; 2020 Mar; 25(6):. PubMed ID: 32168835 [TBL] [Abstract][Full Text] [Related]
18. Toluidine blue O modifies hippocampal amyloid pathology in a transgenic mouse model of Alzheimer's disease. Yuksel M; Biberoglu K; Onder S; Akbulut KG; Tacal O Biochimie; 2018 Mar; 146():105-112. PubMed ID: 29248542 [TBL] [Abstract][Full Text] [Related]
19. Hydromethylthionine enhancement of central cholinergic signalling is blocked by rivastigmine and memantine. Kondak C; Riedel G; Harrington CR; Wischik CM; Klein J J Neurochem; 2022 Jan; 160(2):172-184. PubMed ID: 34855998 [TBL] [Abstract][Full Text] [Related]